These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26629323)

  • 1. JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.
    Nishiya N; Sakamoto Y; Oku Y; Nonaka T; Uehara Y
    World J Biol Chem; 2015 Nov; 6(4):409-18. PubMed ID: 26629323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
    Gendreau SB; Ventura R; Keast P; Laird AD; Yakes FM; Zhang W; Bentzien F; Cancilla B; Lutman J; Chu F; Jackman L; Shi Y; Yu P; Wang J; Aftab DT; Jaeger CT; Meyer SM; De Costa A; Engell K; Chen J; Martini JF; Joly AH
    Clin Cancer Res; 2007 Jun; 13(12):3713-23. PubMed ID: 17575237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
    PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA; El-Emam AA; El-Gohary NS
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Zhang M; Wang Y; Wang J; Liu Z; Shi J; Li M; Zhu Y; Wang S
    Chem Pharm Bull (Tokyo); 2020; 68(10):971-980. PubMed ID: 32999149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compound 15c, a Novel Dual Inhibitor of EGFR
    Chen G; Bao Y; Weng Q; Zhao Y; Lu X; Fu L; Chen L; Liu Z; Zhang X; Liang G
    Front Pharmacol; 2019; 10():1533. PubMed ID: 31998131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.
    Ray P; Tan YS; Somnay V; Mehta R; Sitto M; Ahsan A; Nyati S; Naughton JP; Bridges A; Zhao L; Rehemtulla A; Lawrence TS; Ray D; Nyati MK
    Oncotarget; 2016 Oct; 7(42):68597-68613. PubMed ID: 27612423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Dynamics Analysis of Binding of Kinase Inhibitors to WT EGFR and the T790M Mutant.
    Park J; McDonald JJ; Petter RC; Houk KN
    J Chem Theory Comput; 2016 Apr; 12(4):2066-78. PubMed ID: 27010480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.
    Wurz RP; Pettus LH; Ashton K; Brown J; Chen JJ; Herberich B; Hong FT; Hu-Harrington E; Nguyen T; St Jean DJ; Tadesse S; Bauer D; Kubryk M; Zhan J; Cooke K; Mitchell P; Andrews KL; Hsieh F; Hickman D; Kalyanaraman N; Wu T; Reid DL; Lobenhofer EK; Andrews DA; Everds N; Guzman R; Parsons AT; Hedley SJ; Tedrow J; Thiel OR; Potter M; Radinsky R; Beltran PJ; Tasker AS
    ACS Med Chem Lett; 2015 Sep; 6(9):987-92. PubMed ID: 26396685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
    Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFR
    Wang Y; Lai H; Fan X; Luo L; Duan F; Jiang Z; Wang Q; Leung ELH; Liu L; Yao X
    Front Pharmacol; 2018; 9():728. PubMed ID: 30038571
    [No Abstract]   [Full Text] [Related]  

  • 14. Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.
    Song X; Liu X; Ding X
    J Mol Recognit; 2017 Apr; 30(4):. PubMed ID: 27891677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation.
    Chen Y; Wang Y; Zhao L; Wang P; Sun J; Bao R; Li C; Liu N
    Cancer Biol Med; 2018 Feb; 15(1):39-51. PubMed ID: 29545967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.
    Yamada T; Takeuchi S; Fujita N; Nakamura A; Wang W; Li Q; Oda M; Mitsudomi T; Yatabe Y; Sekido Y; Yoshida J; Higashiyama M; Noguchi M; Uehara H; Nishioka Y; Sone S; Yano S
    Oncogene; 2013 Sep; 32(37):4427-35. PubMed ID: 23045273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
    Qin X; Li Z; Yang L; Liu P; Hu L; Zeng C; Pan Z
    Bioorg Med Chem; 2016 Jul; 24(13):2871-2881. PubMed ID: 27234887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering the molecular mechanism of enhanced tumor activity of the EGFR variant T790M/L858R using melanoma cell lines.
    Shao H; Wells A
    Front Oncol; 2023; 13():1163504. PubMed ID: 37333807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptor.
    Yang Z; Yang H; Ai Y; Zhang L; Li Z; Wan S; Xu X; Zhang H; Wu S; Zhang J; Zhang T
    Eur J Pharm Sci; 2020 Sep; 152():105463. PubMed ID: 32668314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer.
    Sun P; Qu Y; Wang Y; Wang J; Wang X; Sheng J
    J Cancer; 2021; 12(13):3900-3908. PubMed ID: 34093797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.